KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBITDA (2016 - 2025)

CRISPR Therapeutics AG's EBITDA history spans 11 years, with the latest figure at -$130.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 184.08% year-over-year to -$130.8 million; the TTM value through Dec 2025 reached -$578.6 million, down 57.95%, while the annual FY2025 figure was -$578.6 million, 57.95% down from the prior year.
  • EBITDA for Q4 2025 was -$130.8 million at CRISPR Therapeutics AG, down from -$105.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $759.1 million in Q2 2021 and bottomed at -$208.6 million in Q2 2025.
  • The 5-year median for EBITDA is -$116.8 million (2021), against an average of -$68.5 million.
  • The largest annual shift saw EBITDA skyrocketed 1052.88% in 2021 before it tumbled 184.08% in 2025.
  • A 5-year view of EBITDA shows it stood at -$145.5 million in 2021, then increased by 28.57% to -$104.0 million in 2022, then soared by 194.32% to $98.1 million in 2023, then tumbled by 146.95% to -$46.0 million in 2024, then crashed by 184.08% to -$130.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's EBITDA are -$130.8 million (Q4 2025), -$105.5 million (Q3 2025), and -$208.6 million (Q2 2025).